GlassScriptPhysician profile
Laura Danielle Young
NPI 1629310347
$872.05
in general payments reported to CMS, 2019-2025
22 companies · $151 in 2025
The $151 reported for 2025 was less than what a typical Gynecology provider received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $19.32 · 2021: $30.45 · 2023: $259 · 2024: $412 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $822.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $822.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $176.90 | 2023-2024 | Cologuard Collection Kit |
| Baxter Healthcare | $114.77 | 2024 | Tisseel, Perclot |
| Pfizer INC. | $57.05 | 2023-2024 | |
| Heron Therapeutics, INC. | $55.14 | 2025 | Aponvie |
| Astrazeneca Pharmaceuticals LP | $51.06 | 2023-2024 | Tezspire |
| Novo Nordisk INC | $48.83 | 2021-2024 | Ozempic, Rybelsus, Tresiba |
| Hologic Sales and Service, LLC | $46.48 | 2023-2025 | Fluent Fluid Management System, Myosure Tissue Removal Device, Omni Hysteroscope |
| Otsuka America Pharmaceutical, INC. | $33.71 | 2023-2024 | Rexulti |
| Lilly USA, LLC | $32.56 | 2023-2024 | Jardiance, Zepbound, Emgality |
| Axonics, INC. | $30.86 | 2021-2023 | Axonics |
| Glaxosmithkline, LLC. | $27.01 | 2024 | Nucala |
| Astellas Pharma US INC | $25.01 | 2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $23.55 | 2024 | Trintellix |
| Abbott Laboratories | $21.69 | 2024 | Xience Sierra |
| Allergan, INC. | $19.32 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $17.72 | 2023 | Prolastin-C Liquid |
| Merck Sharp & Dohme LLC | $17.45 | 2025 | Winrevair |
| Lundbeck LLC | $15.93 | 2024 | Rexulti |
| Exeltis, USA INC. | $14.63 | 2023 | Slynd |
| Sumitomo Pharma America, INC. | $14.38 | 2025 | Gemtesa |
| Organon LLC | $14.31 | 2025 | Nexplanon |
| Corcept Therapeutics | $13.69 | 2024 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.